News & Updates
Inside Innovation
The latest news and advances from the world's most exciting life science cluster.
Seattle biotech Alpine Immune Sciences raises $91M for drug development
Alpine Immune Sciences announced it is raising approximately $91 million to continue developing two drugs through a private placement. Frazier Life Sciences Public Fund is
Startup A-Alpha Bio sets out to solve a major protein problem facing big pharma
A-Alpha Bio, a Seattle-based startup raised $20 million in a Series A funding round to continue studying which proteins bind with each other. Moving forward
Impel NeuroPharma, fresh off IPO, gets FDA approval for nasal spray that treats migraines
Impel NeuroPharma announced Trudhesa, a drug used to treat migraines, has officially received approval from the U.S. Food and Drug Administration. John Hoekman originally co-founded
These biotech and life sciences CEOs made the leap from software startups — here’s how they did it
During an era of mass investment in the biotech industry and vast innovation, many technology company executives are making the switch to the life science
Biotech companies fuel IPO boom in Washington state over the past year
Out of the 11 biotech companies entering the public market in the last year, eight have been from Washington state. Just this summer, three companies,
Bristol Myers Squibb nabs priority review tag for $3.15B arthritis drug Orencia to prevent transplant rejection
Washington-based biotech company, Bristol Myers Squibb, has received a December 23rd decision date from the FDA. If passed, Orencia, a drug originally approved for patients